An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

"Part 1a (dose escalation):~Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))"

"Part 1a (dose escalation):~Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))"

"Part 1a (dose escalation):~Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))"

"Part 1b (dose expansion and optimization):~tulmimetostat doses 1 or 2 QD"

"Part 2:~tulmimetostat Recommended Phase 2 Dose (RP2D) QD"

JSB462 Dose 1 QD

JSB462 Dose 2 QD

The dose of JSB462 QD will be determined based on the totality of data from Part 1a

Androgen Receptor Pathway Inhibitors (ARPI), chemotherapy or Pluvicto (AAA617) at the discretion of the investigator